Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-BRP-020063 is a Gallium-68 labeled radiopharmaceutical designed for positron emission tomography (PET) imaging of Nectin-4 expression in solid tumors. Developed by The First Affiliated Hospital of Soochow University, it specifically targets Nectin-4 (Poliovirus receptor-related protein 4), a cell surface protein frequently overexpressed in various cancers, including bladder, breast, and lung cancers. As a diagnostic tracer, it is used to evaluate the biodistribution, pharmacokinetics, and imaging characteristics of Nectin-4 positive lesions, potentially aiding in patient selection for Nectin-4 targeted therapies like enfortumab vedotin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 68Ga-BRP-020063.